Skip to main content
SpringerLink
Log in

Pursue pneumococcal vaccination policies vigorously

  • New Drugs and Therapeutics
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Austrian R. Confronting drug-resistant pneumococci. Ann Intern Med 1994; 121: 807–9

    PubMed  CAS  Google Scholar 

  2. Givner LB, Woods CR, Abramson JS. The practice of pediatrics in the era of vaccines effective against Haemophilus influenzae type b. Pediatrics 1994; 93: 680–1

    PubMed  CAS  Google Scholar 

  3. Heath K, Strikas R, Stevenson J, et al. Influenza and pneumococcal vaccination among older adults: results of the 1991 National Health Interview Survey (NHIS) [abstract]. Gerontologist 1994 Oct; 34 (Spec. issue): 369

    Google Scholar 

  4. Dumyati G, Treanor JT. Practical use of vaccines to prevent infection with influenza virus and Streptococcus pneumoniae. Clin Imunother 1994; 2: 248–60

    Article  Google Scholar 

  5. 1994 Physicians Genrx. New York: Data Pharmaceutica Inc., 1994: II–1819–21

  6. Centers for Disease Control. Pneumococcal polysaccharide vaccine. MMWR Morb Mortal Wkly Rep 1989; 38: 64–76

    Google Scholar 

  7. Torzillo PJ. Pneumococcal vaccine: current status. Aust NZ J Med 1993; 23: 285–90

    Article  CAS  Google Scholar 

  8. Rodriguez-Barradas MC, Musher DM, Lahart C, et al. Antibody to capsular polysaccharides of Streptococcus pneumoniae after vaccination of human immunodeficiency virus-infected subjects with 23-valent pneumococcal vaccine. J Infect Dis 1992; 165: 553–6

    Article  PubMed  CAS  Google Scholar 

  9. Kroon FP, van Dissel JT, de Jong JC, et al. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals. AIDS 1994; 8: 469–76

    Article  PubMed  CAS  Google Scholar 

  10. Hedlund JU, Kalin ME, Ortqvist AB, et al. Antibody response to pneumococcal vaccine in middle-aged and elderly patients recently treated for pneumonia. Arch Intern Med 1994; 154: 1961–5

    Article  PubMed  CAS  Google Scholar 

  11. Hib vaccines are effective and safe when used appropriately. Drug Ther Perspect 1994 Mar 7; 3(4): 1–4

    Google Scholar 

  12. Fine MJ, Smith MA, Carson CA, et al. Efficacy of pneumococcal vaccination in adults. Arch Intern Med 1994; 154: 2666–77

    Article  PubMed  CAS  Google Scholar 

  13. Shapiro ED, Berg AT, Austrian R, et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991; 325: 1453–60

    Article  PubMed  CAS  Google Scholar 

  14. Gable CB, Holzer SS, Engelhart L, et al. Pneumococcal vaccine. Efficacy and associated cost savings. JAMA 1990; 264: 2910–5

    Article  PubMed  CAS  Google Scholar 

  15. Holzer SS, Gable CB, Friedman RB. Cost-effectiveness of pneumococcal vaccine: implications for managed care. J Res Pharm Econ 1993; 5: 79–95

    Google Scholar 

  16. Rose DN, Schechter CB, Sacks HS. Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. Am J Med 1993; 94: 160–8

    Article  PubMed  CAS  Google Scholar 

  17. Nieminen T, Käyhty H, Eskola J. Mucosal and serum immune response to tetravalent pneumococcal (SPn) conjugate vaccines (SPnD and SPnT) in adults [abstract]. 34th Int Conf Antimicro Ag Chemother 1994; 236

    Google Scholar 

  18. Kennedy D, Derousse C, Anderson E. Immunologic response of 12–18 month old children to licensed pneumococcal polysaccharide vaccine (PS) primed with Streptococcus pneumoniae 19F conjugate vaccine (CV) [abstract]. 34th Int Conf Antimicro Ag Chemother 1994; 236

    Google Scholar 

  19. Kennedy D, Geldmacher K, Anderson E. Immunologic response to licensed pneumococcal polysaccharide vaccine (PS) in infants primed with heptavalent Streptococcus pneumoniae conjugated vaccine (CV) [abstract]. 34th Int Conf Antimicro Ag Chemother 1994; 236

    Google Scholar 

  20. Steinhoff MC, Hogerman D, Madore D. Duration of antibody response and immunologic memory induced by pneumococcal polysaccharide-CRM 197 conjugate vaccines in children [abstract]. Pediatr Res 1994 Apr; 35 Part 2; 197A

    Article  Google Scholar 

  21. Vidarsson G, Sigurdardottir STH, Gudnason T, et al. Antibody responses of infants immunised with Pb6B-TT, consisting of pneumococcal polysaccharide of serotype 6B conjugated to tetanus toxoid [abstract]. 34th Int Conf Antimicro Ag Chemother 1994; 26

    Google Scholar 

  22. Sarnaik S, Kaplan J, Schiffman G, et al. Studies on Pneumococcus vaccine alone or mixed with DTP and on Pneumococcus type 6B and Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugates in two- to five-year-old children with sickle cell anemia. Pediatr Infect Dis 1990; 9: 181–6

    Article  CAS  Google Scholar 

  23. Miculek S, Anderson EL, Gray BM. Opsonophagocidal antibodies to pneumococcus group 6 in infants and children given a new polysaccharide conjugate vaccine [abstract]. Clin Res 1991; 39: 842A

    Google Scholar 

  24. Mendelman PM, Block S, Hedrick J, et al. Immunogenicity of a 7 valent pneumococcal conjugate vaccine in 2 month old infants [abstract]. Pediatr Res 1994 Apr; 35 Part 2: 187A

    Google Scholar 

  25. Herman CJ, Speroff T, Cebul RD. Improving compliance with immunization in the older adult: results of a randomized cohort study. J Am Geriatr Soc 1994; 42: 1154–9

    PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pursue pneumococcal vaccination policies vigorously. Drugs Ther. Perspect 5, 4–7 (1995). https://doi.org/10.2165/00042310-199505070-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-199505070-00002

Keywords

Search

Navigation